Viridian Therapeutics/$VRDN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Ticker
- $VRDN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 252
- Headquarters
- Waltham, United States
- Website
- www.viridiantherapeutics.com
VRDN Metrics
BasicAdvanced
$3.5B
-
-$3.80
1.07
-
Price and volume
Market cap
$3.5B
Beta
1.07
52-week high
$34.29
52-week low
$13.18
Average daily volume
2.7M
Financial strength
Current ratio
14.462
Quick ratio
14.061
Long term debt to equity
0.421
Total debt to equity
0.423
Interest coverage (TTM)
-19.27%
Profitability
EBITDA (TTM)
-467.962
Gross margin (TTM)
-1,078.44%
Net profit margin (TTM)
-1,724.06%
Operating margin (TTM)
-1,781.38%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-36.48%
Return on equity (TTM)
-83.71%
Valuation
Price to revenue (TTM)
124.158
Price to book
7.35
Price to tangible book (TTM)
7.5
Price to free cash flow (TTM)
-9.242
Free cash flow yield (TTM)
-10.82%
Free cash flow per share (TTM)
-3.381
Growth
Revenue change (TTM)
-62.83%
Earnings per share change (TTM)
25.93%
3-year revenue growth (CAGR)
323.24%
10-year revenue growth (CAGR)
20.86%
3-year earnings per share growth (CAGR)
-9.33%
10-year earnings per share growth (CAGR)
-36.81%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
Analyst projections of the future price of Viridian Therapeutics stock.
Bulls say / Bears say
Lumvoa brought in $24.7 million in its first full quarter of sales, with more than 100 patients on treatment. A permanent Medicare billing code takes effect in January 2027, which could help access. (Viridian Therapeutics)
Lumvoa is FDA-approved for thyroid eye disease across active and chronic disease, and its pivotal trials met their primary and secondary endpoints. That broad label gives Viridian a marketed treatment for patients at different stages of the disease. (Managed Healthcare Executive)
Elegrobart met its primary endpoint in phase 3 trials for both active and chronic disease, supporting a planned Q1 2027 filing. If approved, its at-home autoinjector and less frequent dosing could offer a more convenient alternative to infusions. (Viridian Therapeutics, Viridian Therapeutics)
Viridian faces an established rival in Amgen’s Tepezza, which is already a blockbuster, and Amgen has also reported positive late-stage results for a version delivered by on-body injector. That could make it harder for Viridian’s products to win share on convenience alone. (BioPharma Dive)
Commercial traction remains early: Lumvoa generated $24.7 million in quarterly sales against a $101.2 million net loss, while only 30% of covered lives had formal payer policy coverage at quarter-end. Slow reimbursement expansion could limit sales growth while the company continues to spend heavily. (Viridian Therapeutics, Investing.com)
Lumvoa’s label warns of hearing impairment, including potentially permanent hearing loss, as well as infusion reactions, high blood sugar and worsening inflammatory bowel disease. These risks may deter some patients or prescribers from treatment. (Managed Healthcare Executive)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
Upcoming events
No upcoming events
VRDN News
AllArticlesVideos
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
Benzinga3 days ago
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
Business Wire4 days ago
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Business Wire6 days ago
Funds containing VRDN
Fund name | Fund size | $VRDN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.32% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.32% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.32% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.11% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.